Cantargia AB

ST:CANTA Sweden Biotechnology
Market Cap
$86.21 Million
Skr967.10 Million SEK
Market Cap Rank
#19348 Global
#199 in Sweden
Share Price
Skr3.89
Change (1 day)
-3.83%
52-Week Range
Skr1.03 - Skr6.20
All Time High
Skr58.00
About

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more

Cantargia AB (CANTA) - Total Assets

Latest total assets as of September 2025: Skr358.89 Million SEK

Based on the latest financial reports, Cantargia AB (CANTA) holds total assets worth Skr358.89 Million SEK as of September 2025.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Cantargia AB - Total Assets Trend (2011–2024)

This chart illustrates how Cantargia AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

Cantargia AB - Asset Composition Analysis

Current Asset Composition (December 2024)

Cantargia AB's total assets of Skr358.89 Million consist of 96.4% current assets and 3.6% non-current assets.

Asset Category Amount (SEK) % of Total Assets
Cash & Equivalents Skr0.00 19.4%
Accounts Receivable Skr121.79 Million 71.5%
Inventory Skr0.00 0.0%
Property, Plant & Equipment Skr2.31 Million 1.4%
Intangible Assets Skr3.75 Million 2.2%
Goodwill Skr0.00 0.0%

Asset Composition Trend (2011–2024)

This chart illustrates how Cantargia AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Cantargia AB's current assets represent 96.4% of total assets in 2024, an increase from 84.5% in 2011.
  • Cash Position: Cash and equivalents constituted 19.4% of total assets in 2024, down from 80.6% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 15.0% in 2011.
  • Asset Diversification: The largest asset category is accounts receivable at 71.5% of total assets.

Cantargia AB Competitors by Total Assets

Key competitors of Cantargia AB based on total assets are shown below.

Company Country Total Assets
MedPacto Inc
KQ:235980
Korea ₩51.58 Billion
2H0
F:2H0
Germany €15.27 Million
Shenzhen CAU Technology Co Ltd
SHE:000004
China CN¥260.55 Million
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
China CN¥9.58 Billion
Nanhua Bio Medicine Co Ltd
SHE:000504
China CN¥841.96 Million
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
China CN¥509.14 Million
Chengzhi Shareholding Co Ltd
SHE:000990
China CN¥27.52 Billion
Hualan Biological EngineeringInc
SHE:002007
China CN¥16.27 Billion

Cantargia AB - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.00 - 0.00

Lower asset utilization - Cantargia AB generates 0.00x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -125.17% - -18.70%

Negative ROA - Cantargia AB is currently not profitable relative to its asset base.

Cantargia AB - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 5.82 2.41 29.96
Quick Ratio 5.82 2.41 29.96
Cash Ratio 0.00 0.00 0.00
Working Capital Skr293.97 Million Skr 42.22 Million Skr 882.42 Million

Cantargia AB - Advanced Valuation Insights

This section examines the relationship between Cantargia AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 4.22
Latest Market Cap to Assets Ratio 0.45
Asset Growth Rate (YoY) -23.8%
Total Assets Skr170.43 Million
Market Capitalization $76.57 Million USD

Valuation Analysis

Below Book Valuation: The market values Cantargia AB's assets below their book value (0.45 x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Cantargia AB's assets decreased by 23.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Cantargia AB (2011–2024)

The table below shows the annual total assets of Cantargia AB from 2011 to 2024.

Year Total Assets Change
2024-12-31 Skr170.43 Million -23.82%
2023-12-31 Skr223.71 Million -52.88%
2022-12-31 Skr474.80 Million -20.90%
2021-12-31 Skr600.24 Million -35.14%
2020-12-31 Skr925.51 Million +457.35%
2019-12-31 Skr166.06 Million -3.14%
2018-12-31 Skr171.44 Million -37.53%
2017-12-31 Skr274.45 Million +477.66%
2016-12-31 Skr47.51 Million +51.39%
2015-12-31 Skr31.38 Million +55.91%
2014-12-31 Skr20.13 Million +404.52%
2013-12-31 Skr3.99 Million +5.70%
2012-12-31 Skr3.77 Million +57.03%
2011-12-31 Skr2.40 Million --